LNTH Market Analysis
Wall Street coverage
third-party contextWall Street coverage
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
News & Sentiment
50 articles · sorted by dateVia 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeValuation
- Forward P/E
- 14.37
- PEG ratio
- 0.61
- P/B
- 5.01
- P/S (TTM)
- 4.23
- EV/EBITDA
- 14.02
Profitability & growth
- ROE (TTM)
- 22.2%
- Operating margin
- 25.8%
- Revenue growth YoY
- 2.7%
- Dividend yield
- —
- Beta
- -0.03
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About Lantheus Holdings Inc
Company profileLantheus Holdings, Inc. develops, manufactures and markets diagnostic and therapeutic agents and products that assist physicians in the diagnosis and treatment of heart, cancer and other diseases worldwide. The company is headquartered in North Billerica, Massachusetts.
Classification
- Sector
- Healthcare
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 201 BURLINGTON ROAD, BEDFORD, MA
- Fiscal year end
- December
- Latest quarter
- Jun 30, 2026
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
